6 unchanged sentences
For example, if we hold a security that was issued with a fixed interest rate at the then-prevailing rate and the interest rate later rises, we expect that the fair value of our investment will decline.
−Removed: A hypothetical 100 basis point increase in interest rates would have reduced the fair value of our available-for-sale securities at March 31, 2021 by approximately $2.7 million.
−Removed: We have an equity investment in the common stock of TELA Bio, which is publicly traded on the Nasdaq Global Select Market.
−Removed: TELA Bio is measured at fair value on a recurring basis.
−Removed: Changes in the price of its common stock will affect the value of our investment, and we could incur realized or unrealized losses on all or a part of the value of this investment.
−Removed: At March 31, 2021, the value of our investment in TELA Bio was $11.5 million, and a hypothetical 10% decrease in the market price would have caused a decrease in our carrying amount by $1.1 million.
−Removed: See Note 9, Financial Instruments , to our condensed consolidated financial statements included herein for additional information on our equity investments.
−Removed: In July 2020, we issued $402.5 million in aggregate principal amount of our 2025 Notes, which mature in August 2025.
−Removed: Holders may convert their 2025 Notes prior to maturity under certain circumstances.
−Removed: Upon conversion, holders will receive the principal amount of the 2025 Notes and any excess conversion value in cash, shares of our common stock or a combination of cash and shares, at our option.
−Removed: The fair value of the 2025 Notes is impacted by both the fair value of our common stock and interest rate fluctuations.
−Removed: As of March 31, 2021, the estimated fair value of the 2025 Notes was $1,200 per $1,000 principal amount.
−Removed: See Note 8, Debt , to our condensed consolidated financial statements included herein for further discussion of the 2025 Notes.
−Removed: The 2025 Notes bear interest at a fixed rate.
−Removed: At March 31, 2021, all $402.5 million of principal remains outstanding on the 2025 Notes.
−Removed: In March 2017, we issued $345.0 million in aggregate principal amount of our 2022 Notes, which mature in April 2022.
−Removed: In July 2020, we used part of the net proceeds from the issuance of the 2025 Notes discussed above to repurchase $185.0 million aggregate principal of the 2022 Notes in privately-negotiated transactions for an aggregate of approximately $211.1 million in cash, including accrued interest.
−Removed: Holders may convert their 2022 Notes prior to maturity under certain circumstances.
−Removed: Upon conversion, holders will receive the principal amount of the 2022 Notes and any excess conversion value in cash, shares of our common stock or a combination of cash and shares, at our option.
−Removed: The fair value of the 2022 Notes is impacted by both the fair value of our common stock and interest rate fluctuations.
−Removed: The 2022 Notes bear interest at a fixed rate.
−Removed: As of March 31, 2021, the estimated fair value of the 2022 Notes was $1,216 per $1,000 principal amount.
−Removed: See Note 8, Debt , to our condensed consolidated financial statements included herein for further discussion of the 2022 Notes.
−Removed: At March 31, 2021, $160.0 million of principal remains outstanding on the 2022 Notes.
+Added: A hypothetical 100 basis point increase in interest rates would have reduced the fair value of our available-for-sale securities at June 30, 2021 by approximately $2.3 million.
+Added: The fair values of our convertible senior notes are impacted by both the fair value of our common stock and interest rate fluctuations.
+Added: As of June 30, 2021, the estimated fair value of the 2025 Notes was $1,100 per $1,000 principal amount and the estimated fair value of the 2022 Notes was $1,099 per $1,000 principal amount.
+Added: See Note 8, Debt , to our condensed consolidated financial statements included herein for further discussion of our convertible senior notes, which bear interest at a
+Added: Pacira BioSciences, Inc.
+Added: | Q2 2021 Form 10-Q | Page 41
+Added: At June 30, 2021, all $402.5 million of principal remains outstanding on the 2025 Notes, and $160.0 million of principal remains outstanding on the 2022 Notes..
We have agreements with certain vendors and partners that operate in foreign jurisdictions.
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.